CAM2029

DRUG2 trials

Sponsors

Camurus AB

Conditions

Gastro-enteropancreatic Neuroendocrine TumorPolycystic Liver Disease

Phase 2

A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

Active, not recruitingNCT05281328

Camurus ABPolycystic Liver Disease

Start: 2022-06-28End: 2027-08-31Updated: 2025-12-11

Phase 3

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

Active, not recruitingNCT05050942

Camurus ABGastro-enteropancreatic Neuroendocrine Tumor

Start: 2021-10-22End: 2028-07-31Updated: 2025-11-06

Related Papers

Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.

2024-01-165 citations

Methodology of the SORENTO clinical trial: Assessing the efficacy and safety of high exposure octreotide subcutaneous depot in patients with GEP-NETs.

Journal of Clinical Oncology2022-06-011 citations